Xention Limited

Japan Tobacco Inc.

Derek Edward John

David John Madge

Basil Hartzoulakis

John Ford

Richard John Hamlyn

Mushtaq Mulla

Simon James Jones

John Atherall

Sasha Louise Garrett

Nicholas John Palmer

Oliver Gareth Dugdale

Simon Mark Jones

Simon David Edwards

Helen Jane Payne

Lindsay Brown

Derek Roland Pollard

Richard Blunt

Fiona Chan

David Madge

Helen Payne

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X, R, R, R, R, and Rare defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.

Potassium channel blockers

The present invention provides compounds of formula (I): (Formula (I); wherein A, R, R, R, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by K3.1 and/or K3.4 or any heteromultimers thereof, or that require inhibition of K3.1 and/or K3.4 or any heteromultimers thereof.

Thieno-pyrimidines, useful as potassium channel inhibitors

The present invention relates to thienopyrimidine compounds which are potassium channel inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also described.

Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia

Compounds

A compound of formula (I)  Or its salts or pharmaceutically acceptable derivatives thereof wherein; 

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof, wherein R, R, R, R, R, X, and j are defined herein. The compounds are useful as potassium ion channel inhibitors.

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives wherein R, R, R, X, and A are defined herein. The compounds are useful as potassium ion channel inhibitors.

The invention provides compounds of the formula:  These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.

Thieno[2 3-b]pyridines as potassium channel inhibitors

The invention provides compounds of the formula: wherein These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.

Growing community of inventors

Cambridge, United Kingdom

Derek Edward John